0001209191-21-042577.txt : 20210622 0001209191-21-042577.hdr.sgml : 20210622 20210622195243 ACCESSION NUMBER: 0001209191-21-042577 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210618 FILED AS OF DATE: 20210622 DATE AS OF CHANGE: 20210622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lefebvre Eric CENTRAL INDEX KEY: 0001614741 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39303 FILM NUMBER: 211036867 MAIL ADDRESS: STREET 1: C/O TOBIRA THERAPEUTICS, INC. STREET 2: 701 GATEWAY BOULEVARD, #200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001746473 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474272481 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-481-6770 MAIL ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-18 0 0001746473 PLIANT THERAPEUTICS, INC. PLRX 0001614741 Lefebvre Eric C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Medical Officer Common Stock 2021-06-18 4 S 0 8750 28.6215 D 140830 D Common Stock 2021-06-18 4 S 0 3728 29.4308 D 137102 D Common Stock 2021-06-18 4 S 0 22 30.23 D 137080 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.2000 to $29.1900, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.2000 to $29.8500, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. /s/ Mike Ouimette, attorney-in-fact 2021-06-22